Buprenorphine versus methadone for the treatment of opioid dependence: a systematic review and meta-analysis of randomised and observational studies.

[1]  J. Sadek,et al.  Treatment retention in opioid agonist therapy: comparison of methadone versus buprenorphine/naloxone by analysis of daily-witnessed dispensed medication in a Canadian Province , 2022, BMC Psychiatry.

[2]  M. Shaw,et al.  Buprenorphine Compared with Methadone in Pregnancy: A Systematic Review and Meta-Analysis , 2022, Substance use & misuse.

[3]  T. Wild,et al.  Flexible Buprenorphine/Naloxone Model of Care for Reducing Opioid Use in Individuals With Prescription-Type Opioid Use Disorder: An Open-Label, Pragmatic, Noninferiority Randomized Controlled Trial. , 2022, The American journal of psychiatry.

[4]  A. Roth,et al.  Impact of reduced restrictions on buprenorphine prescribing during COVID-19 among patients in a community-based treatment program , 2022, Drug and Alcohol Dependence Reports.

[5]  B. Sproule,et al.  Duration of use and outcomes among people with opioid use disorder initiating methadone and buprenorphine in Ontario: a population‐based propensity‐score matched cohort study , 2022, Addiction.

[6]  S. Springer,et al.  Factors associated with retention on medications for opioid use disorder among a cohort of adults seeking treatment in the community , 2022, Addiction Science & Clinical Practice.

[7]  T. Gomes,et al.  Association Between Increased Dispensing of Opioid Agonist Therapy Take-Home Doses and Opioid Overdose and Treatment Interruption and Discontinuation. , 2022, JAMA.

[8]  S. Nielsen,et al.  Examining the cost and impact of dosing fees among clients in opioid agonist treatment: Results from a cross‐sectional survey of Australian treatment clients , 2022, Drug and alcohol review.

[9]  E. Quinn,et al.  Variation in Initiation, Engagement, and Retention on Medications for Opioid Use Disorder Based on Health Insurance Plan Design , 2022, Medical care.

[10]  K. A. Johansson,et al.  Effectiveness and Safety of Low-Threshold Opioid-Agonist Treatment in Hard-To-Reach Populations with Opioid Dependence , 2021, European Addiction Research.

[11]  J. Stone,et al.  Modeling the population‐level impact of opioid agonist treatment on mortality among people accessing treatment between 2001 and 2020 in New South Wales, Australia , 2021, Addiction.

[12]  G. Dore,et al.  Outcomes of a single-arm implementation trial of extended-release subcutaneous buprenorphine depot injections in people with opioid dependence. , 2021, The International journal on drug policy.

[13]  J. Min,et al.  Assessing the determinants of completing OAT induction and long-term retention: A population-based study in British Columbia, Canada. , 2021, Journal of substance abuse treatment.

[14]  Declan T. Barry,et al.  Twelve-Month Retention in Opioid Agonist Treatment for Opioid Use Disorder Among Patients With and Without HIV , 2021, AIDS and Behavior.

[15]  L. Degenhardt,et al.  Association of Opioid Agonist Treatment With All-Cause Mortality and Specific Causes of Death Among People With Opioid Dependence: A Systematic Review and Meta-analysis. , 2021, JAMA psychiatry.

[16]  B. Linas,et al.  Characterizing initiation, use, and discontinuation of extended-release buprenorphine in a nationally representative United States commercially insured cohort. , 2021, Drug and alcohol dependence.

[17]  T. Dobbins,et al.  The effect of person, treatment and prescriber characteristics on retention in opioid agonist treatment: a 15-year retrospective cohort study. , 2021, Addiction.

[18]  D. Ciccarone.  The rise of illicit fentanyls, stimulants and the fourth wave of the opioid overdose crisis , 2021, Current opinion in psychiatry.

[19]  M. Vogel,et al.  Retention in the Austrian opioid agonist treatment system: a national prospective cohort study , 2021, Harm Reduction Journal.

[20]  P. Korthuis,et al.  HIV clinic-based buprenorphine plus naloxone versus referral for methadone maintenance therapy for treatment of opioid use disorder in HIV clinics in Vietnam (BRAVO): an open-label, randomised, non-inferiority trial. , 2021, The lancet. HIV.

[21]  A. Morera,et al.  Evaluation of functional status among patients undergoing maintenance treatments for opioid use disorders , 2020, Harm Reduction Journal.

[22]  F. Altice,et al.  The Real-World Impact of Dosing of Methadone and Buprenorphine on Retention on Opioid Agonist Therapies in Ukraine. , 2020, Addiction.

[23]  R. Bruno,et al.  Perceptions of extended‐release buprenorphine injections for opioid use disorder among people who regularly use opioids in Australia , 2019, Addiction.

[24]  C. G. Ng,et al.  A comparison of sexual desire in opiate-dependent men receiving methadone and buprenorphine maintenance treatment , 2019, Annals of General Psychiatry.

[25]  Graeme Henderson,et al.  Global patterns of opioid use and dependence: harms to populations, interventions, and future action , 2019, The Lancet.

[26]  C. Tufanaru,et al.  Methodological quality of case series studies: an introduction to the JBI critical appraisal tool , 2019, JBI database of systematic reviews and implementation reports.

[27]  William J. Kowalczyk,et al.  Stress, craving and mood as predictors of early dropout from opioid agonist therapy. , 2019, Drug and alcohol dependence.

[28]  Natalie S Blencowe,et al.  RoB 2: a revised tool for assessing risk of bias in randomised trials , 2019, BMJ.

[29]  E. Nunes,et al.  Long‐term safety of a weekly and monthly subcutaneous buprenorphine depot (CAM2038) in the treatment of adult out‐patients with opioid use disorder , 2019, Addiction.

[30]  P. Haber,et al.  Insomnia and excessive daytime sleepiness in women and men receiving methadone and buprenorphine maintenance treatment , 2019, Substance use & misuse.

[31]  I. Portoghese,et al.  Sexual Functioning and Opioid Maintenance Treatment in Women. Results From a Large Multicentre Study , 2019, Front. Behav. Neurosci..

[32]  Y. Hser,et al.  Criminal justice outcomes over 5 years after randomization to buprenorphine-naloxone or methadone treatment for opioid use disorder. , 2019, Addiction.

[33]  Stefano Tamburin,et al.  Intravenous Misuse of Methadone, Buprenorphine and Buprenorphine-Naloxone in Patients Under Opioid Maintenance Treatment: A Cross-Sectional Multicentre Study , 2019, European Addiction Research.

[34]  Haniye Sadat Sajadi,et al.  Global, regional, and national incidence, prevalence, and years lived with disability for 354 diseases and injuries for 195 countries and territories, 1990–2017: a systematic analysis for the Global Burden of Disease Study 2017 , 2018, The Lancet.

[35]  M. Yücel,et al.  Dynamic associations between opioid use and anhedonia: A longitudinal study in opioid dependence , 2018, Journal of psychopharmacology.

[36]  Y. Hser,et al.  Correlates of Long-Term Opioid Abstinence After Randomization to Methadone Versus Buprenorphine/Naloxone in a Multi-Site Trial , 2018, Journal of Neuroimmune Pharmacology.

[37]  K. Tilling,et al.  The impact of buprenorphine and methadone on mortality: a primary care cohort study in the United Kingdom , 2018, Addiction.

[38]  M. Gore,et al.  Healthcare utilization and costs associated with treatment for opioid dependence , 2018, Journal of medical economics.

[39]  L. Dawkins,et al.  Predictors of heroin abstinence in opiate substitution therapy in heroin-only users and dual users of heroin and crack. , 2018, Addictive behaviors.

[40]  P. Haber,et al.  Constipation and other common symptoms reported by women and men in methadone and buprenorphine maintenance treatment. , 2017, Drug and alcohol dependence.

[41]  Stefano Tamburin,et al.  Erectile dysfunction and quality of life in men receiving methadone or buprenorphine maintenance treatment. A cross-sectional multicentre study , 2017, PloS one.

[42]  J. Leung,et al.  Global prevalence of injecting drug use and sociodemographic characteristics and prevalence of HIV, HBV, and HCV in people who inject drugs: a multistage systematic review , 2017, The Lancet. Global health.

[43]  J. Samet,et al.  Addiction consultation services - Linking hospitalized patients to outpatient addiction treatment. , 2017, Journal of substance abuse treatment.

[44]  A. Dunlop,et al.  QT interval prolongation in opioid agonist treatment: analysis of continuous 12‐lead electrocardiogram recordings , 2017, British journal of clinical pharmacology.

[45]  A. Rahimi-Movaghar,et al.  Drop-out from a drug treatment clinic and associated reasons. , 2017, Eastern Mediterranean health journal = La revue de sante de la Mediterranee orientale = al-Majallah al-sihhiyah li-sharq al-mutawassit.

[46]  L. Gowing,et al.  Supervised dosing with a long-acting opioid medication in the management of opioid dependence. , 2017, The Cochrane database of systematic reviews.

[47]  L. Degenhardt,et al.  A systematic review of injecting-related injury and disease among people who inject drugs. , 2017, Drug and alcohol dependence.

[48]  G. Dunn,et al.  Pathways through opiate use and offending: A systematic review , 2017, The International journal on drug policy.

[49]  T. Vos,et al.  Guidelines for Accurate and Transparent Health Estimates Reporting: the GATHER statement , 2016, PLoS medicine.

[50]  Ahmed N. Hassan.  Lower rates of consistent urine drug tests for prescribed psychotropic medications among patients on opioid replacement therapy. , 2016, Drug and alcohol dependence.

[51]  M. Hernán,et al.  ROBINS-I: a tool for assessing risk of bias in non-randomised studies of interventions , 2016, British Medical Journal.

[52]  W. Ling,et al.  Long-term outcomes after randomization to buprenorphine/naloxone versus methadone in a multi-site trial. , 2016, Addiction.

[53]  Stephanie Lake,et al.  Health outcomes associated with illicit prescription opioid injection:A systematic review , 2016, Journal of addictive diseases.

[54]  A. Pelander,et al.  New psychoactive substances as part of polydrug abuse within opioid maintenance treatment revealed by comprehensive high‐resolution mass spectrometric urine drug screening , 2016, Human psychopharmacology.

[55]  N. Laird,et al.  Meta-analysis in clinical trials revisited. , 2015, Contemporary clinical trials.

[56]  G. Woody,et al.  Opioid addicted buprenorphine injectors: drug use during and after 12-weeks of buprenorphine-naloxone or methadone in the Republic of Georgia. , 2015, Journal of substance abuse treatment.

[57]  A. Wachholtz,et al.  Co-morbid pain and opioid addiction: long term effect of opioid maintenance on acute pain. , 2014, Drug and alcohol dependence.

[58]  Albert M. Kopak,et al.  A naturalistic comparison of the effectiveness of methadone and two sublingual formulations of buprenorphine on maintenance treatment outcomes: findings from a retrospective multisite study. , 2014, Experimental and clinical psychopharmacology.

[59]  R. Brooner,et al.  A Comparison of Characteristics and Outcomes of Opioid-Dependent Patients Initiating Office-Based Buprenorphine or Methadone Maintenance Treatment , 2014, Substance abuse.

[60]  George F Borm,et al.  The Hartung-Knapp-Sidik-Jonkman method for random effects meta-analysis is straightforward and considerably outperforms the standard DerSimonian-Laird method , 2014, BMC Medical Research Methodology.

[61]  R. Mattick,et al.  Buprenorphine maintenance versus placebo or methadone maintenance for opioid dependence. , 2014, The Cochrane database of systematic reviews.

[62]  L. Amato,et al.  Maintenance agonist treatments for opiate-dependent pregnant women. , 2013, The Cochrane database of systematic reviews.

[63]  G. Woody,et al.  Methadone and buprenorphine-naloxone are effective in reducing illicit buprenorphine and other opioid use, and reducing HIV risk behavior--outcomes of a randomized trial. , 2013, Drug and alcohol dependence.

[64]  R. Blondell,et al.  Primary care patient characteristics associated with completion of 6-month buprenorphine treatment. , 2013, Addictive behaviors.

[65]  R. Bruno,et al.  Correlates of pain in an in-treatment sample of opioid-dependent people. , 2013, Drug and alcohol review.

[66]  K. O’grady,et al.  Retention in methadone and buprenorphine treatment among African Americans. , 2013, Journal of substance abuse treatment.

[67]  L. Phillips,et al.  Predictors of diabetes mellitus and abnormal blood glucose in patients receiving opioid maintenance treatment. , 2013, The American journal on addictions.

[68]  Ayman Fareed,et al.  Comparison of QTc Interval Prolongation for Patients in Methadone Versus Buprenorphine Maintenance Treatment: A 5-Year Follow-Up , 2013, Journal of addictive diseases.

[69]  R. Blondell,et al.  A Preliminary Study Comparing Methadone and Buprenorphine in Patients with Chronic Pain and Coexistent Opioid Addiction , 2013, Journal of addictive diseases.

[70]  C. Baldassarre,et al.  Buprenorphine/naloxone versus methadone in opioid dependence: a longitudinal survey. , 2011, European review for medical and pharmacological sciences.

[71]  I. Maremmani,et al.  Do methadone and buprenorphine have the same impact on psychopathological symptoms of heroin addicts? , 2011, Annals of general psychiatry.

[72]  R. Holland,et al.  The SUMMIT trial: a field comparison of buprenorphine versus methadone maintenance treatment. , 2010, Journal of substance abuse treatment.

[73]  W. Vanderplasschen,et al.  Quality of life among opiate-dependent individuals: A review of the literature. , 2010, The International journal on drug policy.

[74]  M. Schaub,et al.  Feasibility of buprenorphine and methadone maintenance programmes among users of home made opioids in Ukraine. , 2010, The International journal on drug policy.

[75]  A. Grinshpoon,et al.  Improved Quality of Life, Clinical, and Psychosocial Outcomes Among Heroin-dependent Patients on Ambulatory Buprenorphine Maintenance , 2010, Substance use & misuse.

[76]  Louisa Degenhardt,et al.  Opioid agonist pharmacotherapy in New South Wales from 1985 to 2006: patient characteristics and patterns and predictors of treatment retention. , 2009, Addiction.

[77]  D. Moher,et al.  Preferred reporting items for systematic reviews and meta-analyses: the PRISMA Statement , 2009, BMJ : British Medical Journal.

[78]  T. Clausen,et al.  Prevalence and clinical relevance of corrected QT interval prolongation during methadone and buprenorphine treatment: a mortality assessment study. , 2009, Addiction.

[79]  J. Attia,et al.  Hypogonadism in men receiving methadone and buprenorphine maintenance treatment. , 2009, International journal of andrology.

[80]  C. Leonardi,et al.  Opioid maintenance therapy suppresses alcohol intake in heroin addicts with alcohol dependence: Preliminary results of an open randomized study , 2008, Progress in Neuro-Psychopharmacology and Biological Psychiatry.

[81]  Steven A. Branstetter,et al.  Buprenorphine-naloxone versus methadone maintenance therapy: A randomised double-blind trial with opioid-dependent patients , 2008 .

[82]  M. Soyka,et al.  Retention rate and substance use in methadone and buprenorphine maintenance therapy and predictors of outcome: results from a randomized study. , 2008, The international journal of neuropsychopharmacology.

[83]  A. Winstock,et al.  Patients' help-seeking behaviours for health problems associated with methadone and buprenorphine treatment. , 2008, Drug and alcohol review.

[84]  P. Psaltis,et al.  Electrocardiogram Characteristics of Methadone and Buprenorphine Maintained Subjects , 2008, Journal of addictive diseases.

[85]  G. Bigelow,et al.  QT-interval effects of methadone, levomethadyl, and buprenorphine in a randomized trial. , 2007, Archives of internal medicine.

[86]  G. Perugi,et al.  Substance use and quality of life over 12 months among buprenorphine maintenance-treated and methadone maintenance-treated heroin-addicted patients. , 2007, Journal of substance abuse treatment.

[87]  C. Rück,et al.  A Stepped Care Strategy Using Buprenorphine and Methadone Versus Conventional Methadone Maintenance in Heroin Dependence: A Randomized Controlled Trial , 2007 .

[88]  G. Jensen,et al.  Syncope and QT prolongation among patients treated with methadone for heroin dependence in the city of Copenhagen , 2007, Heart.

[89]  Jason M. White,et al.  Maintenance Pharmacotherapy for Opioid Dependence and SF-36 Health Status: A Comparison With General Population Norms and Other Chronic Disorders , 2006 .

[90]  E. Cozzolino,et al.  Multimodal drug addiction treatment: a field comparison of methadone and buprenorphine among heroin- and cocaine-dependent patients. , 2006, Journal of substance abuse treatment.

[91]  G. Kemmler,et al.  Opioid Addicts at Admission vs. Slow-Release Oral Morphine, Methadone, and Sublingual Buprenorphine Maintenance Treatment Participants , 2006, Substance use & misuse.

[92]  R. Jagsch,et al.  Opioid plasma concentrations in methadone‐and buprenorphine‐maintained patients , 2005, Addiction biology.

[93]  G. Kemmler,et al.  Sublingual Buprenorphine and Methadone Maintenance Treatment: A Three-Year Follow-Up of Quality of Life Assessment , 2005, TheScientificWorldJournal.

[94]  M. Malaguarnera,et al.  Randomized clinical trial to compare the effects of methadone and buprenorphine on the immune system in drug abusers , 2005, Psychopharmacology.

[95]  T. Kosten,et al.  Methadone versus buprenorphine with contingency management or performance feedback for cocaine and opioid dependence. , 2005, The American journal of psychiatry.

[96]  S. Seiler,et al.  [Buprenorphine and methadone to opiate addicts--a randomized trial]. , 2005, Tidsskrift for den Norske laegeforening : tidsskrift for praktisk medicin, ny raekke.

[97]  A. Harris,et al.  A randomised trial of the cost effectiveness of buprenorphine as an alternative to methadone maintenance treatment for heroin dependence in a primary care setting , 2005, PharmacoEconomics.

[98]  J. Bell,et al.  Depressive symptoms during buprenorphine vs. methadone maintenance: findings from a randomised, controlled trial in opioid dependence , 2004, European Psychiatry.

[99]  G. Gerra,et al.  Buprenorphine versus methadone for opioid dependence: predictor variables for treatment outcome. , 2004, Drug and alcohol dependence.

[100]  G. Bammer,et al.  Implementing buprenorphine treatment in community settings in Australia: experiences from the Buprenorphine Implementation Trial. , 2004, The American journal on addictions.

[101]  R. Mattick,et al.  Serious adverse events in the Australian National Evaluation of Pharmacotherapies for Opioid Dependence (NEPOD). , 2004, Addiction.

[102]  J. Ahmadi,et al.  Controlled, randomized trial in maintenance treatment of intravenous buprenorphine dependence with naltrexone, methadone or buprenorphine: a novel study , 2003, European journal of clinical investigation.

[103]  H. Hinterhuber,et al.  Buprenorphine versus methadone maintenance treatment in an ambulant setting: a health-related quality of life assessment. , 2003, Addiction.

[104]  Jason M. White,et al.  Buprenorphine versus methadone maintenance therapy: a randomized double-blind trial with 405 opioid-dependent patients. , 2003, Addiction.

[105]  R. Stohler,et al.  Double-blind randomized trial of buprenorphine and methadone in opiate dependence. , 2001, Drug and alcohol dependence.

[106]  M. Stitzer,et al.  A comparison of levomethadyl acetate, buprenorphine, and methadone for opioid dependence. , 2000, The New England journal of medicine.

[107]  G. Gessa,et al.  Buprenorphine: a controlled clinical trial in the treatment of opioid dependence. , 2000, Drug and alcohol dependence.

[108]  S. Kasper,et al.  Buprenorphine versus methadone maintenance for the treatment of opioid dependence. , 1999 .

[109]  P. Jatlow,et al.  Desipramine in opioid-dependent cocaine abusers maintained on buprenorphine vs methadone. , 1999, Archives of general psychiatry.

[110]  D. Ladewig,et al.  Comparison of Buprenorphine and Methadone in the Treatment of Opioid Dependence , 1998, European Addiction Research.

[111]  D. Ziedonis,et al.  Buprenorphine vs methadone maintenance treatment for concurrent opioid dependence and cocaine abuse. , 1997, Archives of general psychiatry.

[112]  W. Ling,et al.  A controlled trial comparing buprenorphine and methadone maintenance in opioid dependence. , 1996, Archives of general psychiatry.

[113]  M. Stitzer,et al.  Buprenorphine versus methadone in the treatment of opioid-dependent cocaine users , 1994, Psychopharmacology.

[114]  M. Stitzer,et al.  Comparison of buprenorphine and methadone in the treatment of opioid dependence. , 1994, The American journal of psychiatry.

[115]  D. Ziedonis,et al.  Buprenorphine versus Methadone Maintenance for Opioid Dependence , 1993, The Journal of nervous and mental disease.

[116]  J. Jaffe,et al.  A controlled trial of buprenorphine treatment for opioid dependence. , 1992, JAMA.

[117]  M. Lapeyre-Mestre,et al.  [Opiate substitution treatment's cycles in a five-year followed-up cohort in ambulatory practice]. , 2013, Therapie.

[118]  I. Cassis,et al.  Opioid Maintenance in Primary Care: a case register based comparison , 2013 .

[119]  L. Marsch,et al.  Buprenorphine and methadone maintenance in jail and post-release: a randomized clinical trial. , 2009, Drug and alcohol dependence.

[120]  B. Mégarbane,et al.  Does High-Dose Buprenorphine Cause Respiratory Depression? , 2006, Toxicological reviews.

[121]  M. Ahmadi,et al.  Treatment of Intravenous Buprenorphine Dependence A Randomized Open Clinical Trial , 2003 .

[122]  D. Ziedonis,et al.  Cocaine Use in Buprenorphine-vs. Methadone-Maintained Patients , 1994 .